Veloxis Pharmaceuticals AS logo

VELO - Veloxis Pharmaceuticals AS Share Price

DKK5.98 0.0  0.0%

Last Trade - 24/02/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £51.3m
Position in Universe th / 1794
Bullish
Bearish
Unlock VELO Revenue
Momentum
Relative Strength (%)
1m -1.17%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
6.79 22.0 2.10 9.19 30.2 39.5 89.7 146.3 +42.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2019, Veloxis Pharmaceuticals AS revenues increased 97% to $54.5M. Net income totaled $7.7M vs. loss of $4.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VELO Revenue Unlock VELO Revenue

Net Income

VELO Net Income Unlock VELO Revenue

Normalised EPS

VELO Normalised EPS Unlock VELO Revenue

PE Ratio Range

VELO PE Ratio Range Unlock VELO Revenue

Dividend Yield Range

VELO Dividend Yield Range Unlock VELO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VELO EPS Forecasts Unlock VELO Revenue
Profile Summary

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a Denmark-based commercial-stage specialty pharmaceutical company. The Company operates in the United States (US) through its subsidiary, Veloxis Pharmaceuticals Inc, based in Cary, North Carolina, US. The Company’s products include: Envarsus XR (tacrolimus extended-release tablets), a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant, as well as Fenoglide for the treatment of dyslipidemia in the United States. Envarsus XR is based upon the Company's patented delivery technology, MeltDose, which is designed to help the absorption and bioavailability of select orally administered drugs.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated March 21, 2002
Public Since November 13, 2006
No. of Shareholders: 8,723
No. of Employees: 60
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 1,739,741,590
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VELO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VELO
Upcoming Events for VELO
Frequently Asked Questions for Veloxis Pharmaceuticals AS
What is the Veloxis Pharmaceuticals AS share price?

As of 24/02/20, shares in Veloxis Pharmaceuticals AS are trading at DKK5.98, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Veloxis Pharmaceuticals AS share price performed this year?

Shares in Veloxis Pharmaceuticals AS are currently trading at DKK5.98 and the price has moved by 86.29% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Veloxis Pharmaceuticals AS price has moved by 0.100k% over the past year.

What are the analyst and broker recommendations for Veloxis Pharmaceuticals AS?

Of the analysts with advisory recommendations for Veloxis Pharmaceuticals AS, there are there are currently 0 "buy" , 0 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Veloxis Pharmaceuticals AS is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will Veloxis Pharmaceuticals AS next release its financial results?

Veloxis Pharmaceuticals AS is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the Veloxis Pharmaceuticals AS dividend yield?

Veloxis Pharmaceuticals AS does not currently pay a dividend.

Does Veloxis Pharmaceuticals AS pay a dividend?

Veloxis Pharmaceuticals AS does not currently pay a dividend.

When does Veloxis Pharmaceuticals AS next pay dividends?

Veloxis Pharmaceuticals AS does not currently pay a dividend.

How do I buy Veloxis Pharmaceuticals AS shares?

To buy shares in Veloxis Pharmaceuticals AS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Veloxis Pharmaceuticals AS?

Shares in Veloxis Pharmaceuticals AS are currently trading at DKK5.98, giving the company a market capitalisation of £n/a.

Where are Veloxis Pharmaceuticals AS shares listed? Where are Veloxis Pharmaceuticals AS shares listed?

Here are the trading details for Veloxis Pharmaceuticals AS:

Country of listing: Denmark
Exchange: CPH
Ticker Symbol: VELO
What kind of share is Veloxis Pharmaceuticals AS?

We were not able to load our ranking data for Veloxis Pharmaceuticals AS

Is there a Veloxis Pharmaceuticals AS share price forecast 2020?

We were not able to load any forecast data for Veloxis Pharmaceuticals AS.

How can I tell whether the Veloxis Pharmaceuticals AS share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veloxis Pharmaceuticals AS. Over the past six months, the relative strength of its shares against the market has been 20.75%. At the current price of DKK5.98, shares in Veloxis Pharmaceuticals AS are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Veloxis Pharmaceuticals AS PE Ratio?

We were not able to find PE ratio data for Veloxis Pharmaceuticals AS.

Who are the key directors of Veloxis Pharmaceuticals AS?

We were unable to find the directors for Veloxis Pharmaceuticals AS.

Who are the major shareholders of Veloxis Pharmaceuticals AS?

Here are the top five shareholders of Veloxis Pharmaceuticals AS based on the size of their shareholding:

Asahi Kasei Corp Corporation
Percentage owned: 100% (1.74bn shares)
Candriam S.A. (France) Investment Advisor
Percentage owned: 0.26% (4.58m shares)
Candriam Risk Arbitrage Mutual Fund
Percentage owned: 0.26% (4.58m shares)
GAM Star (lux) - Merger Arbitrage Mutual Fund
Percentage owned: 0.11% (1.87m shares)
GAM Capital Management (Switzerland) AG Investment Advisor/Hedge Fund
Percentage owned: 0.11% (1.87m shares)
Similar to VELO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.